GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (OTCPK:MLLCF) » Definitions » Valuation Rank

Molecular Partners AG (Molecular Partners AG) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Molecular Partners AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Molecular Partners AG Valuation Rank Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Molecular Partners AG (Molecular Partners AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (OTCPK:MLLCF) » Definitions » Valuation Rank
Comparable Companies
XSWX:NWRN XSWX:SANN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN XSWX:KNRS XSWX:XLS XSWX:IDIA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
MOLN:USA MOLNz:UK 0QXX:UK 6ML0:Germany MOLN:Switzerland
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Website
https://www.molecularpartners.com
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.